|

DOC1021 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Diakonos Oncology Corporation2

Indications

  • Cancer2
  • Refractory Melanoma1
  • Glioblastoma (GBM)1

Birmingham, Alabama1 trial

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

The University of Alabama

Phase 1/2

Gilbert, Arizona1 trial

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Banner MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.